Selection of hepatitis B virus polymerase mutants with enhanced replication by lamivudine treatment after liver transplantation.
暂无分享,去创建一个
[1] M. Manns,et al. Cross-Resistance Testing of Antihepadnaviral Compounds Using Novel Recombinant Baculoviruses Which Encode Drug-Resistant Strains of Hepatitis B Virus , 2001, Antimicrobial Agents and Chemotherapy.
[2] C. Chu,et al. Clearance of the original hepatitis B virus YMDD‐motif mutants with emergence of distinct lamivudine‐resistant mutants during prolonged lamivudine therapy , 2000, Hepatology.
[3] D. Nokes,et al. Predictions of the emergence of vaccine-resistant hepatitis B in The Gambia using a mathematical model , 2000, Epidemiology and Infection.
[4] M. Manns,et al. The Enhancer I Core Region Contributes to the Replication Level of Hepatitis B Virus In Vivo and In Vitro , 2000, Journal of Virology.
[5] R. Thomssen,et al. Hepatitis B Virus Core Gene Mutations Which Block Nucleocapsid Envelopment , 2000, Journal of Virology.
[6] D. Pillay,et al. Outcome of lamivudine resistant hepatitis B virus infection in the liver transplant recipient , 2000, Gut.
[7] S. Hammer. Antiretroviral Resistance Testing Comes of Age , 2000, Antiviral therapy.
[8] C. Shih,et al. Subtype-Independent Immature Secretion and Subtype-Dependent Replication Deficiency of a Highly Frequent, Naturally Occurring Mutation of Human Hepatitis B Virus Core Antigen , 1999, Journal of Virology.
[9] H. Hsu,et al. Changes of hepatitis B surface antigen variants in carrier children before and after universal vaccination in taiwan , 1999, Hepatology.
[10] E. Schiff,et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. , 1999, The New England journal of medicine.
[11] C. Pannecouque,et al. Activity of non-nucleoside reverse transcriptase inhibitors against HIV-2 and SIV. , 1999, AIDS.
[12] C. Chu,et al. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy , 1999, Hepatology.
[13] M. Manns,et al. The Pre‐S region determines the intracellular localization and appearance of hepatitis B virus , 1999, Hepatology.
[14] O. Pappo,et al. Association of lamivudine resistance in recurrent hepatitis B after liver transplantation with advanced hepatic fibrosis. , 1999, Transplantation.
[15] C. Shih,et al. The Mechanism of an Immature Secretion Phenotype of a Highly Frequent Naturally Occurring Missense Mutation at Codon 97 of Human Hepatitis B Virus Core Antigen , 1999, Journal of Virology.
[16] M. Manns,et al. Mutational pattern of hepatitis B virus on sequential therapy with famciclovir and lamivudine in patients with hepatitis B virus reinfection occurring under hbig immunoglobulin after liver transplantation , 1999, Hepatology.
[17] E. Schiff,et al. Multicenter study of lamivudine therapy for hepatitis B after liver transplantation , 1999, Hepatology.
[18] F. Zoulim,et al. Transient selection of a hepatitis B virus polymerase gene mutant associated with a decreased replication capacity and famciclovir resistance , 1999, Hepatology.
[19] K. Hertogs,et al. Patterns of Resistance and Cross-Resistance to Human Immunodeficiency Virus Type 1 Reverse Transcriptase Inhibitors in Patients Treated with the Nonnucleoside Reverse Transcriptase Inhibitor Loviride , 1998, Antimicrobial Agents and Chemotherapy.
[20] W. Carman,et al. Current status of HBV vaccine escape variants – a mathematical model of their epidemiology , 1998, Journal of viral hepatitis.
[21] R. D. de Man,et al. The sequential occurrence of viral mutations in a liver transplant recipient re-infected with hepatitis B: hepatitis B immune globulin escape, famciclovir non-response, followed by lamivudine resistance resulting in graft loss. , 1998, Journal of hepatology.
[22] N. Leung,et al. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. , 1998, The New England journal of medicine.
[23] Y. Cheng,et al. Role of additional mutations outside the YMDD motif of hepatitis B virus polymerase in L(-)SddC (3TC) resistance. , 1998, Biochemical pharmacology.
[24] J. Wands,et al. Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective , 1998, Hepatology.
[25] A. Lok,et al. Hepatitis B virus S mutants in liver transplant recipients who were reinfected despite hepatitis B immune globulin prophylaxis , 1998, Hepatology.
[26] T. Berg,et al. Hepatitis B virus with antigenically altered hepatitis B surface antigen is selected by high‐dose hepatitis B immune globulin after liver transplantation , 1998, Hepatology.
[27] M. Manns,et al. A preS mutation isolated from a patient with chronic hepatitis B infection leads to virus retention and misassembly. , 1997, Gastroenterology.
[28] C. Crumpacker,et al. Attenuated replication of human immunodeficiency virus type 1 with a didanosine-selected reverse transcriptase mutation , 1997, Journal of virology.
[29] J. Hoofnagle,et al. THE TREATMENT OF CHRONIC VIRAL HEPATITIS , 1997 .
[30] E. De Clercq,et al. Multiple drug resistance to nucleoside analogues and nonnucleoside reverse transcriptase inhibitors in an efficiently replicating human immunodeficiency virus type 1 patient strain. , 1996, The Journal of infectious diseases.
[31] M. Manns,et al. Hepatitis B virus envelope variation after transplantation with and without hepatitis B immune globulin prophylaxis , 1996, Hepatology.
[32] E. Elias,et al. Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine , 1996, Hepatology.
[33] D. Tyrrell,et al. Mutation in HBV RNA‐dependent DNA polymerase confers resistance to lamivudine in vivo , 1996, Hepatology.
[34] W. Keulen,et al. Reduced replication of 3TC‐resistant HIV‐1 variants in primary cells due to a processivity defect of the reverse transcriptase enzyme. , 1996, The EMBO journal.
[35] D. Häussinger,et al. Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. , 1996, The New England journal of medicine.
[36] E. Schiff,et al. A preliminary trial of lamivudine for chronic hepatitis B infection. , 1995, The New England journal of medicine.
[37] H. Conjeevaram,et al. Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B. , 1995, The New England journal of medicine.
[38] P. Boyer,et al. Analysis of mutations at position 184 in reverse transcriptase of human immunodeficiency virus type 1 , 1995, Antimicrobial agents and chemotherapy.
[39] Jianping Ding,et al. Locations of anti-AIDS drug binding sites and resistance mutations in the three-dimensional structure of HIV-1 reverse transcriptase. Implications for mechanisms of drug inhibition and resistance. , 1994, Journal of molecular biology.
[40] M. Manns,et al. Prostaglandin E plus famciclovir--a new concept for the treatment of severe hepatitis B after liver transplantation. , 1994, Transplantation.
[41] P. Boyer,et al. Sensitivity of wild-type human immunodeficiency virus type 1 reverse transcriptase to dideoxynucleotides depends on template length; the sensitivity of drug-resistant mutants does not. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[42] G. Alexander,et al. Liver transplantation in European patients with the hepatitis B surface antigen. , 1993, The New England journal of medicine.
[43] T. Wright,et al. Molecular virology and pathogenesis of hepatitis B , 1993, The Lancet.
[44] H. Thomas,et al. Genetic variation in hepatitis B virus. , 1992, Gastroenterology.
[45] C. Wittekind,et al. Liver transplantation in HBs antigen (HBsAg) carriers. Prevention of hepatitis B virus (HBV) recurrence by passive immunization. , 1991, Journal of hepatology.
[46] J. Summers,et al. A domain of the hepadnavirus capsid protein is specifically required for DNA maturation and virus assembly , 1991, Journal of virology.
[47] H. Will,et al. Hepatitis B virus unable to secrete e antigen. , 1991, Gastroenterology.
[48] A. Zuckerman,et al. Vaccine-induced escape mutant of hepatitis B virus , 1990, The Lancet.
[49] J. Hoofnagle,et al. Randomized, controlled trial of recombinant human α-interferon in patients with chronic hepatitis B , 1988 .
[50] A. Lok,et al. LONG-TERM FOLLOW-UP IN A RANDOMISED CONTROLLED TRIAL OF RECOMBINANT α2-INTERFERON IN CHINESE PATIENTS WITH CHRONIC HEPATITIS B INFECTION , 1988, The Lancet.
[51] Ching-lung Lai,et al. PLACEBO-CONTROLLED TRIAL OF RECOMBINANT α2-INTERFERON IN CHINESE HBsAg-CARRIER CHILDREN , 1987, The Lancet.
[52] R. Hoover,et al. SERUM CHOLESTEROL AND CANCER IN THE NHANES I EPIDEMIOLOGIC FOLLOWUP STUDY , 1987, The Lancet.
[53] M. Coleman,et al. RESPONSE OF INTESTINAL MUCOSA TO GLUTEN CHALLENGE IN AUTISTIC SUBJECTS , 1979, The Lancet.